Clinical trials: Hypertension, Pulmonary Artery
Pulmonary Arterial Hypertension
Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution
This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib inhalation solution (AER-901) in healthy adult…
- Trial name
- NCT04903730
- Testing
- AER-901 Solution for Nebulization
- Where
- Australia
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Aerami Therapeutics
Pulmonary Arterial Hypertension
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose.
- Trial name
- VIP Extend (NCT03795428)
- Testing
- Pemziviptadil (PB1046) Injection
- Where
- 16 sites in United States
- Volunteers
- 25 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)
This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study.
- Trial name
- NCT00993408
- Testing
- ACT-293987 (NS-304)
- Where
- 8 sites in Austria, Belgium and 6 more
- Volunteers
- 43 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III.
- Trial name
- NCT05934526
- Testing
- Seralutinib, Generic Dry Powder Inhaler
- Where
- 166 sites in United States, Argentina and 29 more
- Volunteers
- 390 people
- Sponsor
- GB002, Inc.
Pulmonary Arterial Hypertension
A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study. Primary objectives: To evaluate the psychometric characteristics of reliability and construct validity of the French, Italian and Spanish…
- Trial name
- ORCHESTRA (NCT02081690)
- Testing
- Macitentan
- Where
- 39 sites in France, Italy and 1 more
- Volunteers
- 160 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension…
- Trial name
- IMPAHCT (NCT05036135)
- Testing
- AV-101
- Where
- 128 sites in United States, Argentina and 24 more
- Volunteers
- 202 people
- Sponsor
- Aerovate Therapeutics
Pulmonary Arterial Hypertension
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP…
- Trial name
- NCT05649748
- Testing
- Treprostinil Palmitil
- Where
- 45 sites in United States, Argentina and 13 more
- Volunteers
- 91 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects…
- Trial name
- ATHENA-1 (NCT00617305)
- Testing
- Ambrisentan, Sildenafil, Tadalafil
- Where
- 30 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
This multicenter, open label, Phase 2a study is designed to evaluate the effect of inhaled RT234 delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with Pulmonary Arterial…
- Trial name
- NCT05343637
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
- Where
- 3 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT04712669
- Testing
- rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 108 people
- Sponsor
- Altavant Sciences GmbH
Pulmonary Arterial Hypertension
Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study is to evaluate long-term safety and tolerability of continued treatment with CS1.
- Trial name
- NCT06321705
- Testing
- CS1
- Where
- Sweden
- Sponsor
- Cereno Scientific AB
Pulmonary Arterial Hypertension
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
- Trial name
- NCT00477269
- Testing
- Imatinib mesylate
- Where
- 13 sites in United States, Austria and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
TReatment Of Pulmonary HYpertension 1-US Study
The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and…
- Trial name
- TROPHY 1-US (NCT02835950)
- Testing
- Therapeutic Intra-Vascular UltraSound (TIVUS™) System
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH).
- Trial name
- NCT07600723
- Testing
- Sotatercept, Background PAH Therapy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology).
- Trial name
- NCT00367770
- Testing
- Tracleer®
- Where
- 17 sites in United States, Australia and 9 more
- Volunteers
- 37 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Selonsertib in Adults With Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of selonsertib (GS-4997) on pulmonary vascular resistance (PVR), as measured by right heart catheterization (RHC) in adults with pulmonary arterial hypertension (PAH).
- Trial name
- ARROW (NCT02234141)
- Testing
- Selonsertib
- Where
- 46 sites in United States, Canada and 6 more
- Volunteers
- 151 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT02652429
- Testing
- Inhaled Nitric Oxide
- Where
- 17 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
This is an observational, multicenter, single-day, Phase 2 study. This study will include a 14-day Screening Period and Study Day 1 clinic visit.
- Trial name
- PRN (NCT03888365)
- Testing
- Treprostinil, Non-Treprostinil PAH Medications
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- United Therapeutics
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
Heart Failure Patients With Pulmonary Hypertension
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension
Prospective, single-arm, multicenter First in Human study to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Pulmonary Hypertension
- Trial name
- PreVail-PH (NCT05951166)
- Testing
- Gradient Denervation System
- Where
- 2 sites in Georgia
- Volunteers
- 5 people
- Sponsor
- Gradient Denervation Technologies